A new study has shown that a new class of drug candidates developed at The Scripps Research Institute increases bone mass by expanding bone formation (deposition of new bone) and bone turnover (a normal process of replacement of old bone).
New safety data from a study of patients with advanced Parkinson's disease five years after gene transfer-mediated delivery of the neuroprotective factor neurturin directly to patients' brains reveal no serious adverse events related to the treatment. The encouraging long-term safety profile of the surgically administered adeno-associated virus (AAV2)-neurturin gene therapy is described in an article in Human Gene Therapy.
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus with the potential of improving pathological liver conditions. Using model mice, they confirmed that when a certain enzyme is inhibited, HCV particle production is reduced leading to an improvement of pathological liver conditions. They thereby identified a new drug target for the development of new HCV drugs.
The study of the mechanism of reactivation of acetylcholinesterase inhibited by organophosphates is still a challenge for theoretical chemists since mechanistic studies, involve electronic transfer and breaking and formation of chemical bonds.
An international team of researchers led by ETH scientists has been studying the factors influencing the development of different blood cells. Their research shows that certain molecular mechanisms are not as relevant as previously assumed. This finding helps to improve our understanding of diseases such as leukemia and anemia.
Drugs that stop the overproduction of proteins by cancer cells may shut them down, but it also shuts down production of essential proteins in healthy cells. UC Berkeley researchers have found a protein with an active site that opens & initiates translation only when the protein binds to a small subset of mRNAs -- those critical to regulating the growth and proliferation of cell. Drugs to block this protein may allow a more targeted drug approach.
Antibodies that specifically protect against Zika infection have been identified in mice, report Washington University School of Medicine in St. Louis researchers on July 27 in Cell. This is the second publication in recent weeks (another paper showing human Zika antibodies appeared in Science on July 14) that explores the surfaces that the antibodies target on the virus. The information will help inform the development of vaccines, diagnostics, and antibody-based prophylactic and therapeutic agents.
An international team of scientists who searched out specimens from museums and remote Arctic islands has identified a rare new species of beaked whale that ranges from northern Japan across the Pacific Ocean to Alaska's Aleutian Islands.
A new study of the immunosuppressive treatment routinely used to prevent graft rejection in rats that serve as test subjects for human stem cell therapies to combat retinal degeneration has linked the immunosuppressive regimen to reduced visual function. This finding has important implications for interpreting the results of studies that use common rat model for translational stem cell research, as described in an article in Journal of Ocular Pharmacology and Therapeutics.
Zika virus has become a household word. It can cause microcephaly, a birth defect where a baby's head is smaller than usual. Additionally, it is associated with Guillain-Barré syndrome, a neurological disorder that could lead to paralysis and even death. However, how this microbe replicates in the infected cells remains a mystery. Now, an international team has unraveled the puzzle of how Zika virus replicates and published their finding in Springer's journal Protein & Cell.